Literature DB >> 27207512

Variants in Genes Controlling Oxidative Metabolism Contribute to Lower Hepatic ATP Independent of Liver Fat Content in Type 1 Diabetes.

Sofiya Gancheva1, Alessandra Bierwagen1, Kirti Kaul1, Christian Herder1, Peter Nowotny1, Sabine Kahl2, Guido Giani3, Birgit Klueppelholz3, Birgit Knebel4, Paul Begovatz1, Klaus Strassburger3, Hadi Al-Hasani4, Jesper Lundbom1, Julia Szendroedi2, Michael Roden5.   

Abstract

Type 1 diabetes has been recently linked to nonalcoholic fatty liver disease (NAFLD), which is known to associate with insulin resistance, obesity, and type 2 diabetes. However, the role of insulin resistance and hyperglycemia for hepatic energy metabolism is yet unclear. To analyze early abnormalities in hepatic energy metabolism, we examined 55 patients with recently diagnosed type 1 diabetes. They underwent hyperinsulinemic-normoglycemic clamps with [6,6-(2)H2]glucose to assess whole-body and hepatic insulin sensitivity. Hepatic γATP, inorganic phosphate (Pi), and triglyceride concentrations (hepatocellular lipid content [HCL]) were measured with multinuclei magnetic resonance spectroscopy ((31)P/(1)H-MRS). Glucose-tolerant humans served as control (CON) (n = 57). Whole-body insulin sensitivity was 44% lower in patients than in age- and BMI-matched CON. Hepatic γATP was 15% reduced (2.3 ± 0.6 vs. 2.7 ± 0.6 mmol/L, P < 0.001), whereas hepatic Pi and HCL were similar in patients when compared with CON. Across all participants, hepatic γATP correlated negatively with glycemia and oxidized LDL. Carriers of the PPARG G allele (rs1801282) and noncarriers of PPARGC1A A allele (rs8192678) had 21 and 13% lower hepatic ATP concentrations. Variations in genes controlling oxidative metabolism contribute to a reduction in hepatic ATP in the absence of NAFLD, suggesting that alterations in hepatic mitochondrial function may precede diabetes-related liver diseases.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27207512     DOI: 10.2337/db16-0162

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  6 in total

1.  Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance.

Authors:  Elisa Álvarez Hernández; Sabine Kahl; Anett Seelig; Paul Begovatz; Martin Irmler; Yuliya Kupriyanova; Bettina Nowotny; Peter Nowotny; Christian Herder; Cristina Barosa; Filipa Carvalho; Jan Rozman; Susanne Neschen; John G Jones; Johannes Beckers; Martin Hrabě de Angelis; Michael Roden
Journal:  J Clin Invest       Date:  2017-01-23       Impact factor: 14.808

2.  Distinct alterations of gut morphology and microbiota characterize accelerated diabetes onset in nonobese diabetic mice.

Authors:  Marie-Christine Simon; Anna Lena Reinbeck; Corinna Wessel; Julia Heindirk; Tomas Jelenik; Kirti Kaul; Juan Arreguin-Cano; Alexander Strom; Michael Blaut; Fredrik Bäckhed; Volker Burkart; Michael Roden
Journal:  J Biol Chem       Date:  2019-12-10       Impact factor: 5.157

3.  Associations among perfluorooctanesulfonic/perfluorooctanoic acid levels, nuclear receptor gene polymorphisms, and lipid levels in pregnant women in the Hokkaido study.

Authors:  Sumitaka Kobayashi; Fumihiro Sata; Houman Goudarzi; Atsuko Araki; Chihiro Miyashita; Seiko Sasaki; Emiko Okada; Yusuke Iwasaki; Tamie Nakajima; Reiko Kishi
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

4.  Reduced hepatocellular lipid accumulation and energy metabolism in patients with long standing type 1 diabetes mellitus.

Authors:  Peter Wolf; Paul Fellinger; Lorenz Pfleger; Sabina Smajis; Hannes Beiglböck; Martin Gajdošík; Christian-Heinz Anderwald; Siegfried Trattnig; Anton Luger; Yvonne Winhofer; Martin Krššák; Michael Krebs
Journal:  Sci Rep       Date:  2019-02-22       Impact factor: 4.379

5.  Allopurinol ameliorates liver injury in type 1 diabetic rats through activating Nrf2.

Authors:  Fei Zeng; Jierong Luo; Hong Han; Wenjie Xie; Lingzhi Wang; Ronghui Han; Hao Chen; Yin Cai; Huansen Huang; Zhengyuan Xia
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

6.  Enhancement of Adiponectin Ameliorates Nonalcoholic Fatty Liver Disease via Inhibition of FoxO1 in Type I Diabetic Rats.

Authors:  Xiang Xie; Dan Yan; Haobo Li; Qiqi Zhu; Jun Li; Yong-Ping Fang; Chi Wai Cheung; Michael G Irwin; Zhengyuan Xia; Qingquan Lian
Journal:  J Diabetes Res       Date:  2018-08-16       Impact factor: 4.011

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.